Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2012 1
2014 1
2015 2
2016 2
2018 5
2019 2
2020 5
2021 10
2022 9
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Basho RK, et al. Among authors: white jb. JCO Precis Oncol. 2024 Mar;8:e2300124. doi: 10.1200/PO.23.00124. JCO Precis Oncol. 2024. PMID: 38484209
Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy.
Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Musall BC, et al. Among authors: white jb. J Magn Reson Imaging. 2024 Jan 31. doi: 10.1002/jmri.29267. Online ahead of print. J Magn Reson Imaging. 2024. PMID: 38294179
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs.
Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Zhou Z, et al. Among authors: white jb. Annu Int Conf IEEE Eng Med Biol Soc. 2023 Jul;2023:1-4. doi: 10.1109/EMBC40787.2023.10340987. Annu Int Conf IEEE Eng Med Biol Soc. 2023. PMID: 38083160
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens.
Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. Chen H, et al. Among authors: white jb. Ther Adv Med Oncol. 2023 Aug 2;15:17588359231189422. doi: 10.1177/17588359231189422. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37547448 Free PMC article.
A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer.
Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, Ma J, Rauch GM. Hwang KP, et al. Among authors: white jb. Radiol Imaging Cancer. 2023 Jul;5(4):e230009. doi: 10.1148/rycan.230009. Radiol Imaging Cancer. 2023. PMID: 37505106 Free PMC article.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. Yam C, et al. Among authors: white jb. Breast Cancer Res Treat. 2023 Jun;199(3):457-469. doi: 10.1007/s10549-023-06929-9. Epub 2023 Apr 15. Breast Cancer Res Treat. 2023. PMID: 37061619 Clinical Trial.
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
Abuhadra N, Sun R, Bassett RL Jr, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Abuhadra N, et al. Among authors: white jb. Invest New Drugs. 2023 Jun;41(3):391-401. doi: 10.1007/s10637-023-01357-4. Epub 2023 Apr 12. Invest New Drugs. 2023. PMID: 37043123 Clinical Trial. No abstract available.
46 results